Bookbuilding IPO | ₹28 Cr | Listed at BSE SME | Wed, Jul 9, 2025 - Fri, Jul 11, 2025
Asston Pharmaceuticals IPO is a book build issue of ₹27.56 crores. The issue is entirely a fresh issue of 0.22 crore shares of ₹27.56 crore.
Asston Pharmaceuticals IPO bidding started from Jul 9, 2025 and ended on Jul 11, 2025. The allotment for Asston Pharmaceuticals IPO was finalized on Jul 14, 2025. The shares got listed on BSE SME on Jul 16, 2025.
Asston Pharmaceuticals IPO price band is set at ₹123 per share. The lot size for an application is 1,000. The minimum amount of investment required by an individual investor (retail) is ₹2,46,000 (2,000 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (3,000 shares), amounting to ₹3,69,000.
Sobhagya Capital Options Pvt.Ltd. is the book running lead manager and Maashitla Securities Pvt.Ltd. is the registrar of the issue. The Market Maker of the company is JSK Securities & Services Pvt.Ltd..
Refer to Asston Pharmaceuticals IPO RHP for detailed Information.
IPO Open
Wed, Jul 9, 2025
IPO Close
Fri, Jul 11, 2025
Issue Price
₹123 per share
Market Cap (Pre-IPO)
₹104.70 Cr
| IPO Date | 9 to 11 Jul, 2025 |
| Listed on | Wed, Jul 16, 2025 |
| Face Value | ₹10 per share |
| Price Band | ₹115 to ₹123 |
| Issue Price | ₹123 per share |
| Lot Size | 1,000 Shares |
| Sale Type | Fresh capital only |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Total Issue Size | 22,41,000 shares (agg. up to ₹28 Cr) |
| Reserved for Market Maker | 1,13,000 shares JSK Securities & Services Pvt.Ltd. (agg. up to ₹1 Cr) |
| Fresh Issue (Ex Market Maker) | 21,28,000 shares (agg. up to ₹26 Cr) |
| Net Offered to Public | 21,28,000 shares (agg. up to ₹26 Cr) |
| Share Holding Pre Issue | 62,71,360 shares |
| Share Holding Post Issue | 85,12,360 shares |
| BSE Script Code | 544445 |
| ISIN | INE0SJX01015 |
Asston Pharmaceuticals IPO comprises a total issue size of 22,41,000 shares. The net offer to the public is 21,28,000 shares, after excluding 1,13,000 shares allotted on a firm basis. Of the Net offer 10,60,000 (49.81%) are allocated to QIB, 3,22,000 (15.13%) allocated to NII 7,46,000 (35.06%) allocated to RII.
| Investor Category | Shares Offered | % of Net Issue | % of Total Issue |
|---|---|---|---|
| QIB Shares Offered | 10,60,000 | 49.81% | 47.30% |
| − Anchor Investor Shares Offered | 6,35,000 | 28.34% | |
| − QIB (Ex. Anchor) Shares Offered | 4,25,000 | 18.96% | |
| NII (HNI) Shares Offered | 3,22,000 | 15.13% | 14.37% |
| − bNII > ₹10L | 2,15,000 | 9.59% | |
| − sNII < ₹10L | 1,07,000 | 4.77% | |
| Retail Shares Offered | 7,46,000 | 35.06% | 33.29% |
| Firm Reservations | |||
| Market Maker Shares Offered | 1,13,000 | 5.04% | |
| Total Shares Offered | 22,41,000 | 100.00% | 100.00% |
Investors can bid for a minimum of 2,000 shares and in multiples of 1,000 shares thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 2,000 | ₹2,46,000 |
| Individual investors (Retail) (Max) | 2 | 2,000 | ₹2,46,000 |
| S-HNI (Min) | 3 | 3,000 | ₹3,69,000 |
| S-HNI (Max) | 8 | 8,000 | ₹9,84,000 |
| B-HNI (Min) | 9 | 9,000 | ₹11,07,000 |
Asston Pharmaceuticals IPO raises ₹7.81 crore from anchor investors. Asston Pharmaceuticals IPO Anchor bid date is July 8, 2025.
📝 Anchor Investors Letter (PDF)
| Bid Date | Tue, Jul 8, 2025 |
| Shares Offered | 6,35,000 |
| Anchor Portion (₹ Cr.) | 7.81 |
| Anchor lock-in period end date for 50% shares (30 Days) | Wed, Aug 13, 2025 |
| Anchor lock-in period end date for remaining shares (90 Days) | Sun, Oct 12, 2025 |
Incorporated in 2019, Asston Pharmaceuticals Limited is engaged in the business of pharmaceuticals, specializing in exporting healthcare products globally.
The company offers a diverse range of products, including tablets, capsules, sachets, and syrups. Its product portfolio encompasses various therapeutic categories, such as analgesics, antibiotics, antifungals, vitamins, and more.
The company manufactures pharmaceutical products for direct sales and also on a contract manufacturing or loan license basis, primarily working on a principle-to-principle approach with various marketers.
The company is FDA certified by both Central and State FDA, accredited by NQA (Nuclear Quality Assurance), and complies with Quality Management System (QMS) standards, ensuring high-quality manufacturing.
Products:
As of 3 July 2025, the company has 46 Permanent employees and 6 contractual employees in various departments.
Competitive Strengths:
Asston Pharmaceuticals Ltd.'s revenue increased by 62% and profit after tax (PAT) rose by 218% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 31 May 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 31.83 | 28.12 | 20.26 | 13.69 |
| Total Income | 6.21 | 25.61 | 15.84 | 7.19 |
| Profit After Tax | 1.32 | 4.33 | 1.36 | 1.06 |
| EBITDA | 1.93 | 6.16 | 2.55 | 1.52 |
| NET Worth | 12.04 | 10.72 | 6.39 | 1.99 |
| Reserves and Surplus | 5.77 | 4.45 | 5.61 | 1.29 |
| Total Borrowing | 7.83 | 7.26 | 6.82 | 5.25 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit | 6.00 |
| 2 | Funding the incremental working capital requirements of the Company | 13.00 |
| 3 | Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company | 1.00 |
| 4 | General Corporate Purposes | 3.95 |
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 50.56% |
| ROCE | 51.25% |
| Debt/Equity | 0.68 |
| RoNW | 40.36% |
| PAT Margin | 17.27% |
| EBITDA Margin | 24.60% |
| Price to Book Value | 12.07 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 6.90 | 9.32 |
| P/E (x) | 17.83 | 13.2 |
| Promoter Holding | 68.76% | 50.66% |
| Market Cap | ₹104.70 Cr. |
The Asston Pharmaceuticals IPO is subscribed 186.55 times on July 11, 2025 5:04:34 PM (Day 3). The public issue subscribed 172.06 times in the individual investors category, 85.76 times in the QIB category, and 353.14 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) | Shares Offered | Shares bid for | Total Application |
|---|---|---|---|---|
| QIB | 85.76 | 4,25,000 | 3,64,49,000 | 0 |
| NII* | 353.14 | 3,22,000 | 11,37,10,000 | 0 |
| bNII (bids above ₹10L) | 424.47 | 2,15,000 | 9,12,62,000 | 79,695 |
| sNII (bids below ₹10L) | 210.85 | 1,07,000 | 2,25,61,000 | 79,695 |
| Individual Investors | 172.06 | 7,46,000 | 12,83,58,000 | 0 |
| Total | 186.55 | 14,93,000 | 27,85,17,000 | 79,695 |
Total Application : 79,695
*Market Maker portion is not included to NII/HNI.
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Issue Management fees including fees and payment to other intermediaries such as Legal Advisors, Registrars and other out of pocket expenses. | 2.22 |
| 2 | Brokerage and selling commission fee for SCSBs, Sponsor Banks and Bankers to the Offer. Brokerage and selling commission and bidding charges for Members of the Syndicate, Registered Brokers, RTAs and CDPs | 0.08 |
| 3 | Printing & Stationery, Distribution, Postage, etc | 0.12 |
| 4 | Advertisement and Marketing Expenses | 1.16 |
| 5 | Stock Exchange Fees, Regulatory and other Expenses | 0.04 |
| Total | 3.61 |
| Price Details | BSE SME |
|---|---|
| Final Issue Price | ₹123.00 |
| Open | ₹119.00 |
| Low | ₹113.05 |
| High | ₹124.95 |
| Last Trade | ₹124.95 |
Lead Manager Reports
Asston Pharmaceuticals IPO is a SME IPO of 22,41,000 equity shares of the face value of ₹10 aggregating up to ₹28 Crores. The issue is priced at ₹123 per share. The minimum order quantity is 1000.
The IPO opens on Wed, Jul 9, 2025, and closes on Fri, Jul 11, 2025.
Maashitla Securities Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE SME.
Zerodha customers can apply online in Asston Pharmaceuticals IPO using UPI as a payment gateway. Zerodha customers can apply in Asston Pharmaceuticals IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Asston Pharmaceuticals IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Asston Pharmaceuticals IPO opens on Wed, Jul 9, 2025 and closes on Fri, Jul 11, 2025.
Asston Pharmaceuticals IPO lot size is 1000, and the minimum amount required for application is ₹2,46,000, with 2 lots being the minimum application size.
You can apply in Asston Pharmaceuticals IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Asston Pharmaceuticals IPO will be done on Monday, July 14, 2025, and the allotted shares will be credited to your demat account by Tue, Jul 15, 2025. Check the Asston Pharmaceuticals IPO allotment status.
The Asston Pharmaceuticals IPO listing date is on Wed, Jul 16, 2025.
